Microarrays permit the analysis of gene expression, DNA sequence variation, protein levels, tissues, cells and other biological and chemical molecules in a massively parallel format. Robust microarray ...

As the scope of proteomics is extremely broad, it is helpful to distinguish among its various aspects before discussing how microarray technology is likely to feature. Over the past decade, the ...

Reviewed by Dr. Tomislav Meštrović, MD, Ph.D. The microarray is a very recent development in the field of biotechnology. Scientists are now able to understand the gene functions of any organism by ...

Carbohydrate microarrays have become essential screening tools for revealing the functions of biomolecules that interact with sugars, providing essential information on the mechanisms of diseases. The ...

Courtesy of CombiMatrix The research community's rapid acceptance of microarrays notwithstanding, technical challenges remain. Biochip developers continue to grapple with these issues while upgrading ...

The microarray is a recently developed technology used in cancer research and in the pharmacological treatment of other diseases such as oral lesions. In this technology, a microscope slide ...

Companies in the microarray sector are trying to take the technology out of core facilities and put it into the hands of individual researchers by developing technologies such as smaller, less-costly ...

Trial represents first-ever CDC-sponsored clinical trial of vaccine delivered via “patch” technology and utilizes Micron’s first-in-class dissolvable microarray technologyResearch builds on ...

The acquisition of the Arizona-based microarray solutions company extends SCHOTT’s manufacturing presence in the United States and strengthens its bioscience capabilities. Customers will benefit from ...

The first study of the use of microarray patches to vaccinate children has shown that the method is safe and induces strong immune responses. The phase 1/2 randomized trial compared results from the ...

- The United States Biomedical Advanced Research and Development Authority (BARDA) has announced Vaxxas will receive US$2 million (AU$3.2 million) as a Concept Stage Winner in its multi-stage $50 ...

The phase 1/2 randomized trial compared results from the measles and rubella vaccine delivered by a microarray patch, a small sticking plaster-like device with an array of microscopic projections that ...